Clinical trials: Liver Neoplasms
Liver Cancer
A Prospective, Multicenter Clinical Trial of Safety and Effectiveness of Nanosecond Knife Ablation for Liver Cancer
This is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers.
- Trial name
- NCT04309747
- Testing
- nanosecond knife liver cancer ablation
- Volunteers
- 190 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Neuroendocrine (NE) Tumors, Liver Metastasis
The Role of Intraoperative Hepatic Ultrasonography in Gastrointestinal or Pancreatic Neuroendocrine Tumor
Background: Liver metastases are common in patients with neuroendocrine neoplasms, but often underestimated by preoperative imaging.
- Trial name
- ECHO-NET (NCT06779708)
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Istituto Clinico Humanitas
Liver Metastasis Colon Cancer, Synchronous Neoplasm
Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer
This single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mCRC) using FOLFOXIRI neoadjuvant regimen and to assess the other outcome including…
- Trial name
- NCT05362825
- Testing
- Neo-adjuvant Chemotherapy FOLFOXIRI Regimen, synchronous resection surgery
- Where
- Vietnam
- Volunteers
- 89 people
- Sponsor
- Cho Ray Hospital
Hepatocellular Carcinoma
Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma
60 patients of radiological, biopsy proven advanced HCC (Hepatocellular carcinoma) patient will be randomized into two groups. Cases group will receive Sorafenib plus vitamin K and control group will receive Sorafenib plus placebo
- Trial name
- NCT02259647
- Testing
- Sorafenib 400mg twice daily + intravenous infusion ofVit K1
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Carcinoma, Hepatocellular
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
The purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma…
- Trial name
- NCT03062358
- Testing
- pembrolizumab, best supportive care (BSC)
- Where
- 41 sites in China, Hong Kong and 3 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatectomy
A Study of Methylprednisolone in People Having Liver Surgery
The purpose of this study is to test whether receiving methylprednisolone before surgery will reduce the side effects of having surgery, such as infections and longer hospital stays.
- Trial name
- NCT07507643
- Testing
- Methylprednisolone
- Where
- 19 sites in United States
- Volunteers
- 750 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Liver Metastases
SAMe in Prevention of Oxaliplatin-associated Liver Injury
This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury
- Trial name
- NCT06258525
- Testing
- Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cedars-Sinai Medical Center
Hepatic Cell Carcinoma
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to…
- Trial name
- NCT06515314
- Testing
- AFP Specific T Cell Receptor T Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Ruiliyuan Biotechnology Co., Ltd.
HCC, Liver Cirrhosis
Open Label Trial of Immunotherapy for Advanced Liver Cancer
The purpose of this study is to evaluate daily dosing of oral immunotherapy hepcortespenlisimut-L (V5) in patients with advanced stage of HCC not amenable to surgical intervention or with recurrent tumor after surgery.
- Trial name
- HCC (NCT02256514)
- Testing
- Daily oral dose of hepcortespenlisimut-L
- Where
- Mongolia
- Volunteers
- 120 people
- Sponsor
- Immunitor LLC
Carcinoma, Hepatocellular
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.
- Trial name
- NCT06530784
- Testing
- Cryoablation, PD-1 antibody and bevacizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Zhongshan Hospital
HBV Infection, HCC - Hepatocellular Carcinoma
Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus
Primary objective: The main objective of this study is to assess the efficacy and safety of a sandwich combination therapy in patients who were infected with HBV or have undergone surgery for hepatitis B virus (HBV)-related…
- Trial name
- NCT07088133
- Testing
- NA(s)+HT-102+FD-001
- Volunteers
- 12 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Metastasis Colon Cancer
TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer
Transarterial chemoembolization (TACE) is an effective, minimally invasive therapy that is widely used for unresectable colorectal cancer liver metastases (CRC-LM) treatment.
- Trial name
- EMBOBEVA (NCT03732235)
- Testing
- TACE+ systemic Bevacizumab, FOLFIRI+Bevacizumab, TACE
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Giammaria Fiorentini
Liver Cancer
Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
This prospective, single-center observational study evaluates the diagnostic accuracy of a novel Folate-targeted Near-Infrared II Carbon Dot (FA-CDots) probe for the ex vivo assessment of Hepatocellular Carcinoma (HCC).
- Trial name
- NCT07295340
- Testing
- Ex Vivo FA-CDots Staining
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Alcohol-related Liver Disease, Cirrhosis, Liver
- Trial name
- CHALNA2 (NCT05623150)
- Testing
- Liver biopsy
- Where
- France
- Volunteers
- 710 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Hepatocellular Carcinoma
Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)
The purpose of this study is to evaluate the anti-tumor effect of sirolimus-based immunosuppressive regimen in patients following living donor liver transplantation for hepatocellular carcinoma exceeding Milan criteria with…
- Trial name
- Sirolimus (NCT01374750)
- Testing
- Sirolimus, m-TOR inhibitor free
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation by Transcatheter Arterial Chemoembolization
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Transcatheter arterial chemoembolization (TACE) is the traditional method for the palliative management of patients with HCC.
- Trial name
- NCT00630240
- Where
- Taiwan
- Volunteers
- 53 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC
Hepatocellular carcinoma (HCC) recurs in up to 60% of patients who undergo resection. Circulating tumor cells (CTC) have been advocated as promotors of the recurrence.
- Conditions
- Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Circulating Tumor Cell
- Trial name
- NCT04800497
- Testing
- Hepatic resection
- Where
- 4 sites in Italy
- Volunteers
- 70 people
- Sponsor
- University of Milano Bicocca
Liver Cancer
Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma
Brachytherapy is a recent technique used in the treatment of tumours and involves the use of radioactive sources brought into close contact with the target tissues.
- Trial name
- NCT00247260
- Testing
- 32P BioSilicon
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- pSiVida Limited
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
This phase II trial studies the side effects and how well nivolumab with or with ipilimumab works in treating patients with liver cancer that can be removed by surgery.
- Trial name
- NCT03222076
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Hepatic Metastasis
Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)(COLD 4)
Palliative radiotherapy is radiation treatment given to help reduce pain or discomfort, or other symptoms related to cancer. This is used commonly for cancer that has spread to the bones and brain, and for many other primary…
- Trial name
- NCT00923897
- Testing
- Palliative RT
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto